Loading clinical trials...
Loading clinical trials...
Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.
Conditions
Interventions
Peginterferon alfa-2a, Ribavirin, Amantadine
Locations
27
Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Universitätsklinikum Mannheim
Mannheim, Baden-Würtemberg, Germany
Universitätsklinikum Heidelberg
Heidelberg, Baden-Württembeg, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany
Klinikum rechts der Isar der TU München
München, Bavaria, Germany
Start Date
November 1, 2005
Last Updated
March 9, 2007
NCT04973605
NCT06189391
NCT07350863
NCT06026319
NCT06138275
NCT05862012
Lead Sponsor
University of Hamburg-Eppendorf
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions